Introduction {#S0001}
============

Doctor-shopping involves visiting multiple doctors with the same health problem and is often observed in outpatient clinics. It has significant consequences for patients and payers, because multiple consultations and overlapping prescriptions are associated with drug misuse, polypharmacy, and increased medical expenses. Changing doctors for the same illness episode without a referral and a link to a history of previous treatment reduces healthcare providers' ability to ensure effective and efficient treatment \[[1](#CIT0001)--[3](#CIT0003)\]. Also, rising expectations of receiving high-quality healthcare have been reported to have an impact on the patient--doctor relationship and to contribute to a switch of doctor \[[4](#CIT0004),[5](#CIT0005)\].

On one hand, patients are entitled to seek high-quality healthcare, but on the other hand, excessive searching for a second opinion contributes to increased costs of treatment and reduces continuity of care. There are many reasons why patients engage in doctor-shopping. Reports from the literature highlight the importance of factors affecting accessibility to healthcare facilities, such as location, opening hours, and waiting times \[[6](#CIT0006)--[8](#CIT0008)\]. Patients visit more doctors when they have a chronic disease or a drug addiction and their health problem remains unresolved despite receiving treatment \[[9](#CIT0009)--[11](#CIT0011)\]. Among factors that reduce doctor-shopping are a proper diagnosis, high patient satisfaction and a good patient--doctor relationship \[[12](#CIT0012),[13](#CIT0013)\].

Extensive studies of doctor-shopping in a broad population of patients have not been published in the literature. There is still an ongoing debate among researchers on definitions used to measure this phenomenon and on how to evaluate its impact on patient well-being and healthcare resource use. We conducted this study in order to improve our knowledge of doctor-shopping and to focus the attention of healthcare providers on its reasons and consequences.

Objective {#S0002}
=========

The aim of this study was to review the literature describing doctor-shoppers in the adult population and to identify factors associated with doctor-shopping behaviour.

Methods {#S0003}
=======

A systematic literature review was performed in PubMed and supplemented by a Google search of grey literature. The search in PubMed was run on the 28 May 2018. No restrictions regarding timeframe and geographical scope were applied. Eligibility criteria were defined according to the PICOS approach and are presented in [Table 1](#T0001). A first reviewer screened records and abstracts as well as selected studies for qualitative analysis and extracted data from selected publications. Doubtful cases were discussed with a second reviewer, and discrepancies were resolved by consensus. The electronic search strategy is presented in [Table 2](#T0002). The following data were extracted: definition of doctor-shopper, disease, treatment, patient characteristics, doctor-shopping rate, special patient needs, and country. 10.1080/20016689.2019.1595953-T0001Table 1.Inclusion and exclusion criteria.PICOInclusion criteriaExclusion criteriaPopulationAdults; patients with any disease in outpatient or inpatient settings.--InterventionAny intervention or diagnostic procedure.--ComparatorNone required.--OutcomeDoctor switch.--Study designCohort study; RCT; case report; abstract; database analysis.Review; letter to the editor; editorial; opinion.10.1080/20016689.2019.1595953-T0002Table 2.Electronic search strategy in PubMed.IDSearch termsNumber of PubMed hits\#1Doctor shopping\[Text Word\]153\#2Doctor shopper\[Text Word\]8\#3Physician shopping\[Text Word\]2\#4Physician shopper\[Text Word\]28\#5Double doctoring\[Text Word\]4\#6Drug seeking patient\[Text Word\]10\#7(physician) AND switch\*2514\#8(doctor) AND switch\*1959\#9\#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6 OR \#7 OR \#82837

Results {#S0004}
=======

Overall, 2885 records were identified in PubMed and 48 in the grey literature, out of which 43 were included in the qualitative synthesis. A PRISMA flow diagram of study selection is shown in [Figure 1](#F0001). 10.1080/20016689.2019.1595953-F0001Figure 1.PRISMA flow diagram.

Definition of doctor-shopping {#S0004-S2001}
-----------------------------

Definitions of doctor-shopping were heterogeneous. The type of the definition depended mostly on the drug and disease studied and the type of source data used in each specific study. The most consistent definitions were used in studies on drug misuse, especially opioids, in which researchers retrospectively evaluated prescriptions using IMS prescription databases or insurance databases. These studies were based on calculations of daily dose that enabled detection of drug overdosing and monitoring the numbers of prescriptions written by different doctors \[[11](#CIT0011),[14](#CIT0014)--[19](#CIT0019)\]. Some studies also included information on the number of pharmacies involved \[[20](#CIT0020)--[25](#CIT0025)\]. Clinical trials and surveys used definitions based on the number of visits during the same illness episode or for the same, often chronic, condition without or within a specified timeframe and without a professional referral. In studies enrolling patients with chronic conditions such as diabetes \[[7](#CIT0007)\], eye floaters \[[26](#CIT0026)\], or nephrolithiasis\[[9](#CIT0009)\], the definition of doctor-shopping specified a higher number of visits, whereas in cases of urgent conditions or infections, definitions specified a timeframe and were, for example, limited to one day \[[27](#CIT0027)\] or to the same illness episode \[[6](#CIT0006),[10](#CIT0010),[12](#CIT0012),[28](#CIT0028)--[34](#CIT0034)\]. Studies focusing on the evaluation of doctor-shopping in general medicine or primary doctor facilities had longer timeframes of 1 year \[[35](#CIT0035),[36](#CIT0036)\], 2 years \[[37](#CIT0037)\], or even 3 years \[[38](#CIT0038)\]. Definitions of doctor-shopping in the studies identified are presented in [Table 3](#T0003). 10.1080/20016689.2019.1595953-T0003Table 3.Definitions of doctor-shopping.ReferenceDefinitionType of studyDisease/drugCepeda 2013 \[[24](#CIT0024)\]\>1 prescription by ≥2 different prescribers with ≥1 day of overlap and filled at ≥3 pharmacies.Retail prescription databaseOpioids (tapentadol IR, oxycodoneCepeda 2013 \[[25](#CIT0025)\]Retail prescription databaseIR)Cepeda 2015 \[[23](#CIT0023)\]Retail prescription databaseOpioidsChenaf 2016 \[[20](#CIT0020),[21](#CIT0021)\]EGB databaseADHDDelorme 2016 \[[22](#CIT0022)\]EGB databaseCodeine, tramadol, chronic painBuprenorphine, naloxone, methadoneLu 2015 \[[14](#CIT0014)\]≥2 prescriptions by different doctors within ≥ 1 day overlapping in the duration of therapy.Insurance databaseInsomnia, zolpidemMcDonald 2014 \[[15](#CIT0015)\]Retail prescription databaseOpioidsNordmann 2013 \[[16](#CIT0016)\]GHI reimbursement databaseOpioidsPonte 2018 \[[11](#CIT0011)\]Insurance databaseOpioidsPradel 2010 \[[17](#CIT0017)\]Insurance databaseBenzodiazepinesRouby 2012 \[[18](#CIT0018)\]Insurance databaseTianeptineSimeone 2017 \[[19](#CIT0019)\]IMS databaseOpioidsMartyres 2004 \[[39](#CIT0039)\]\>1 prescription without specified dose overlap or number of prescribers.Database studyHeroin-related overdoseMorris 2014 \[[40](#CIT0040)\]Prospective study + database studyNarcotics, orthopaedic traumaOkumura 2016 [\[48\]](#CIT0048)Insurance databaseBenzodiazepinesPradel 2004 [\[45\]](#CIT0045)Prescription databaseBuprenorphineAgrawal 2016 [\[7\]](#CIT0007)Visiting ≥1--5 doctors during the same illness episode.QuestionnaireDiabetesChang 2012 [\[28\]](#CIT0028)Insurance databaseColorectal cancerFeng 2013 [\[35\]](#CIT0035)QuestionnaireOverweightGudzune 2014 [\[13\]](#CIT0013)Internet-based surveyOverweightGudzune 2013 [\[37\]](#CIT0037)Claims data, health risk assessmentsOverweightKappa 2016 [\[9\]](#CIT0009)Retrospective study, medical recordsNephrolithiasis, opioidsLeug 2006 [\[29\]](#CIT0029)Case-control studyGeneral practitioner facilityLeug 2003 [\[6\]](#CIT0006)Cross-sectional surveyGeneral practitioner facilityLin 2015 \[[46](#CIT0046)\]Database studyTraditional Chinese medicine usersLo 1994 \[[10](#CIT0010)\]Database studyGovernment outpatient departmentsNorton 2011 \[[30](#CIT0030)\]QuestionnairePrimary care facilityOhira 2012 [\[12\]](#CIT0012)QuestionnaireGeneral medicineSafran 2001 [\[38\]](#CIT0038)Observational study, questionnairePrimary care facilitySato 1999 [\[31\]](#CIT0031)QuestionnairePrimary care facilitySato 1995 [\[32\]](#CIT0032)QuestionnairePrimary care, alternative medicineSiu 2014 [\[33\]](#CIT0033)InterviewOveractive bladderSorbero 2003 [\[36\]](#CIT0036)Tseng 2015 [\[26\]](#CIT0026)Database studyGeneral medicineWang 2010 [\[34\]](#CIT0034)QuestionnaireEye floatersYeung 2004 [\[8\]](#CIT0008)Cohort database studyRespiratory infectionWu 2014 [\[27\]](#CIT0027)Telephone interviewSpecialist outpatient clinicsDatabase studyGeneral practitioner facilityLee 2011 [\[41\]](#CIT0041)Visiting healthcare providers with a special aim.Telephone surveyDemand for advertised drugsStogner 2014 [\[42\]](#CIT0042)SurveyDrug abuse or resellZhang 2017 [\[43\]](#CIT0043)Database studyPrice-shoppingWorley 2014 [\[44\]](#CIT0044)Study focused on experience.InterviewDrug abuse during pregnancyHsieh 2013 [\[47\]](#CIT0047)Hospital changeRetrospective longitudinal studyHepatocellular carcinoma[^1]

Geographical scope of studies on doctor shopping {#S0004-S2002}
------------------------------------------------

Overall, 17 (39.5%) studies were conducted in the USA, out of which 9 were based solely on retrospective data from large databases \[[9](#CIT0009),[11](#CIT0011),[13](#CIT0013),[15](#CIT0015),[19](#CIT0019),[23](#CIT0023)--[25](#CIT0025),[36](#CIT0036)--[44](#CIT0044)\]. Another 8 (18.6%) studies were conducted in France \[[16](#CIT0016)--[18](#CIT0018),[20](#CIT0020)--[22](#CIT0022),[30](#CIT0030),[45](#CIT0045)\], 7 (16.3%) in Taiwan \[[14](#CIT0014),[26](#CIT0026)--[28](#CIT0028),[34](#CIT0034),[46](#CIT0046),[47](#CIT0047)\], 5 (11.6%) in Hong Kong \[[6](#CIT0006),[8](#CIT0008),[10](#CIT0010),[29](#CIT0029),[33](#CIT0033)\], and 4 (9.3%) in Japan \[[12](#CIT0012),[31](#CIT0031),[32](#CIT0032),[48](#CIT0048)\]. There was a one study from Australia and one from India \[[7](#CIT0007),[35](#CIT0035)\]. The studies were performed in countries where patients can visit medical institutions freely under the national health system and/or have access to all institutions and specialists without a referral. The distribution of countries studied is presented in [Figure 2](#F0002). 10.1080/20016689.2019.1595953-F0002Figure 2.Geographical distribution of the studies analysed.

Rate of doctor-shopping {#S0004-S2003}
-----------------------

Overall, 16 (40%) of studies examined the use of strong, addictive drugs such as opioids, antidepressants, or psychoactive drugs, while the others included patients with chronic (e.g., diabetes, cancer, overactive bladder) or frequent disease (e.g., upper respiratory tract infections). The prevalence of doctor-shopping ranged from 0.5% among opioid users in the USA to 38% of patients registered at general practices in Hong Kong. Examples of rates of doctor-shopping across studies that used different methodologies are shown in [Table 4](#T0004). The rate of doctor-shopping varied considerably depending on the disease, the drug studied, and the type of medical service used. The most reliable precise data were provided for database studies on opioid use. These studies also had the lowest risk bias, because they enabled prescriptions and sales of the drugs prescribed to be tracked in retail prescription databases. Studies including patients registered at outpatient and specialist clinics were mostly based on questionnaires that used different timeframes, small samples, and lacked information about people who refused to participate. 10.1080/20016689.2019.1595953-T0004Table 4.Rates of doctor-shopping across identified studies.Disease/drugReference/regionSample sizeRate of doctor-shoppingStimulants, ADHDCepeda 2015 [\[23\]](#CIT0023)4,402,4640.45% any type of shopping behaviourUSA 0.05% heavy shopping behaviourOpioidsCepeda 2013 [\[25\]](#CIT0025)10,910,4510.7% any type of shopping behaviourUSA 0.1% heavy shopping behaviourOpioids,\
non-cancer painChenaf 2016 [\[20\]](#CIT0020)19584.03% for codeineFrance 0.17% for diuretics  8.45% for buprenorphine maintenance treatmentOpioidsDelorme 2016 [\[22\]](#CIT0022)20438.4% for high dosage buprenorphineFrance 0% for methadone  0.2% for diureticsOpioids, nephrolithiasisKappa 2016 [\[9\]](#CIT0009)\
USA20024% received narcotics from ≥1 provider after surgeryZolpidem, insomniaLu 2015 [\[14\]](#CIT0014)\
Taiwan694723.78% for zolpidemGeneral populationLee 2011 [\[41\]](#CIT0041)\
USA299814% of participants whose doctor refused to prescribe a drug switched doctorPatients of specialist outpatient clinicsLeung 2003 [\[6\]](#CIT0006)\
Hong Kong649526.4% of population requiring specialist careGovernment outpatient departmentsLo 1994 [\[10\]](#CIT0010)\
Hong Kong138736%-38% during single illness episodeGeneral medicineSato 1995 [\[32\]](#CIT0032)\
Japan75824.4% visited \>1 medical facility with the same complaintEye floatersTseng 2015 [\[26\]](#CIT0026)\
Japan13435% visited \>1 ophthalmologist

Factors affecting the rate of doctor-shopping {#S0004-S2004}
---------------------------------------------

Risk factors for and protective factors against doctor-shopping have been evaluated in multiple studies. Factors associated with doctor-shopping included predominantly the nature of the disease and comorbidities. Both types of doctor-shoppers (opioid users and patients registered at general and primary doctor practices) shared the same risk factors, such as the presence of mental health disorders, alcohol dependence, and a history of alcohol and active substance misuse disorders \[[9](#CIT0009),[22](#CIT0022),[23](#CIT0023),[30](#CIT0030),[31](#CIT0031),[36](#CIT0036),[40](#CIT0040)\]. Doctor-shoppers were younger and had a lower socioeconomic status than non-doctor-shoppers, particularly among people who misused opioids \[[9](#CIT0009),[20](#CIT0020),[21](#CIT0021),[23](#CIT0023)\]. Patients with chronic diseases, multiple comorbidities, and persistent symptoms were more likely to visit a larger number of healthcare providers \[[10](#CIT0010),[14](#CIT0014),[37](#CIT0037),[41](#CIT0041),[46](#CIT0046),[47](#CIT0047),[48](#CIT0048)\]. A good relationship with a doctor and positive experiences were factors that helped to prevent doctor-shopping \[[33](#CIT0033),[38](#CIT0038)\]. Individuals who consumed opioids and drugs for the treatment of attention deficit hyperactivity disorder (ADHD) and engaged in doctor-shopping were more likely to pay cash and to travel great distances to doctor facilities or pharmacies \[[19](#CIT0019),[24](#CIT0024)\]. Factors contributing to the development of doctor-shopping are summarised in [Table 5](#T0005). 10.1080/20016689.2019.1595953-T0005Table 5.Factors affecting the rate of doctor-shopping.Disease/drugReferenceRisk factorsOpioid usersCepeda 2015 [\[23\]](#CIT0023)\
Delorme 2016 [\[22\]](#CIT0022)Presence of mental health disorders; alcohol dependence; low-income status.PainChenaf 2016 [\[20\]](#CIT0020)Presence of mental health disorders; history of opioid and substance misuse disorders; doctor-shoppers were of younger age and lower income status.Post-surgery due to nephrolithiasis; opioids.Kappa 2016 [\[9\]](#CIT0009)History of mental illness; prior stone procedures; history of preoperative narcotic misuse; younger age; lower income status; less educated.Orthopaedic traumaMorris 2014 [\[40\]](#CIT0040)History of preoperative narcotic misuse; concomitant alcohol misuse; less educated.BenzodiazepinesOkumura 2016 [\[48\]](#CIT0048)Multiple chronic conditions.InsomniaLu 2015 [\[14\]](#CIT0014)Greater number of comorbidities; chronic diseases; younger age; high socioeconomic status.Hepatocellular carcinomaHsieh 2013 [\[47\]](#CIT0047)Hepatitis B carriers; recurrence of hepatocellular carcinoma; younger age; female.Overactive bladderSiu 2014 [\[33\]](#CIT0033)Negative treatment experiences.OverweightGudzune 2013 [\[37\]](#CIT0037)Greater number of comorbidities; mental health diagnosis; diabetes mellitus diagnosis.TCM usersLin 2015 [\[46\]](#CIT0046)Presence of catastrophic illness; history of hospital admission; acupuncture; trauma; dislocation; low income.Outpatient clinicLo 1994 [\[10\]](#CIT0010)Presence of chronic or acute conditions; persistent symptoms.Primary careNorton 2011 [\[30\]](#CIT0030)Presence of psychiatric and mental disorders.Primary careSafran 2001 [\[38\]](#CIT0038)Poor doctor--patient relationship.General medicineLee 2011 [\[41\]](#CIT0041)Presence of cancer and other chronic conditions.General medicineSato 1999 [\[31\]](#CIT0031)Duration of illness; presence of psychiatric disorders; perceived poor and deteriorating health condition; less educated.General medicineSorbero 2003 [\[36\]](#CIT0036)Multiple comorbid conditions; history of drug/alcohol misuse; younger age; female.[^2]

Discussion {#S0005}
==========

This systematic review of the literature showed that doctor-shopping is a common phenomenon. The rate of this phenomenon varies among patient populations with different health problems. For opioids, it can be as low as 0.45% among the broad population that uses opioids, or as high as 24% among patients with a specific reason for opioid use, such as recent surgery for nephrolithiasis. The highest rates were reported for multiple visits to doctors during the same illness episode and were found to involve as many as 38% of patients registered at outpatient clinics. Multiple factors were identified as potential risk factors for doctor-shopping. The most common were multiple comorbid conditions including mental disorders, unresolved health problems, history of drug and other substance misuse, younger age, and poor socioeconomic status. Factors such as a good patient--doctor relationship and a positive patient experience may reduce the rate of doctor-shopping.

Doctor-shopping can signal problems of healthcare system and drug overuse resulting in worsening of health condition of doctor-shoppers. A negative impact of polypharmacy on health has been well documented in the literature \[[49](#CIT0049)\]. Also, changing doctors reduces continuity of care which can translate into worse disease management and increased waiting times as well as increased cost of treatment for both the patients and payers \[[50](#CIT0050)\]. Another reason for analysing the phenomenon of doctor shopping is drug abuse. According to police and regulatory agency perceptions, about 40% of prescription drug diversions were sourced from doctor-shopping; however, many other mechanisms such as thefts, forgeries, smuggling, insurance frauds, internet purchase, in-transit losses, and physician 'pill-mills' were also identified \[[51](#CIT0051)\].

The extent and interest in analysis doctor-shopping depend on the healthcare system structure. The country where the study was conducted is an important factor that may influence the rate of doctor-shopping. In some countries, e.g., in Taiwan, patients have access without restrictions to all institutions and specialists \[[52](#CIT0052)\]. Similarly, in Japan patients can visit medical institutions freely under the national health system \[[12](#CIT0012)\]. In such cases, the absence of a mandatory attempt to treat the condition by a primary care physician (gate keeper) before a referee to a specialist may increase doctor-shopping behaviour \[[47](#CIT0047)\]. In France, visiting another general practitioner requires a small additional payment; however, drugs are prescribed for a shorter period (a maximum of 30 days) compared to other countries \[[16](#CIT0016),[18](#CIT0018)\]. In the UK, patients have more difficulties with changing doctors, because many general practitioners do not accept patients from outside their own catchment area. Additionally, it is more difficult to access specialist care in the UK. Unfortunately, no studies from the UK were identified, so an evaluation of the impact of accessibility to healthcare on the rate of doctor-shopping was not possible.

Heterogeneity in the definitions of the doctor-shopping was linked to heterogeneity in the data sources. Studies using prescription databases or insurance claims assessed the number of overlapping prescriptions, whereas studies using surveys as a source of information evaluated the number of visits to doctors. This organisation of research does not give a full picture of the problems associated with doctor-shopping. The analysis of overlapping prescriptions provides information only about the misuse of selected drugs, but leaves problems such as polypharmacy, comorbidities, and effectiveness of treatment of the primary disease undiscussed. Individuals who misuse certain agents from different classes, e.g., opioids, stimulants, and benzodiazepines, might not be identified as doctor-shoppers in these analyses.

The main limitation of surveys is that participants who complete questionnaires may conceal information about addictions, drug misuse or a true reason for a doctor-shopping. The limitation of claims-based study, although giving accurate information, includes possible discrepancies between claims and patient behaviours; claims for prescriptions do not always indicate that the medication was taken as prescribed.

Prescription drug monitoring programmes that aim to reduce drug abuse report that the number of overall drug prescriptions per person is lower when a patient is on a single schedule in comparison to the number of prescriptions filled for individuals prescribed drugs in multiple schedules \[[53](#CIT0053),[54](#CIT0054)\]. This finding is intuitive, but highlights the possible risks associated with polypharmacy, which is often rooted in a greater number of comorbidities. The presence of multiple comorbidities, both mental and somatic, was identified as a risk factor for doctor-shopping \[[9](#CIT0009),[23](#CIT0023),[31](#CIT0031),[36](#CIT0036),[48](#CIT0048)\].

Little is known on the effective long-term initiatives to reduce doctor-shopping especially in terms of eliminating drug interactions, errors in dosing and polypharmacy. Programs based on the promotion of medication reviews and education of physicians and patients were found to be effective. However, they face problems with the identification of patients at risk for polypharmacy or drug abuse \[[55](#CIT0055)\]. Computerized physician order entry, clinical decision support, and electronic prescriptions systems showed the ability to diminish medication errors in specific therapeutic areas in monitored patients \[[56](#CIT0056),[57](#CIT0057)\]. Introduction of electronic insurance cards with health information and medication history would offer benefits when introduced nationally; however, such solutions require investments in infrastructure \[[58](#CIT0058)\]. Moreover, Taiwanese experience shows that only 73% of physicians review their prescriptions in response to displayed alerts \[[59](#CIT0059)\]. The obstacles mentioned above highlight challenges in the development of useful, easy to use and cheap solution for optimising pharmacological treatment in patients at risk for polypharmacy or drug abuse.

Conclusions {#S0006}
===========

Knowing the characteristics of doctor-shoppers may help identify such patients and reduce the associated waste of medical resources, but concerns about the misuse of drug or healthcare resources should not prevent proper disease management. Further research is needed to cover a wider range of diseases and countries, and to examine the effect of healthcare regulations on doctor-shopping prevalence and costs.
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[^1]: ADHD, attention deficit hyperactivity disorder; EGB, Echantillon Generaliste des Beneficiaires; GHI, general health insurance; IR, immediate release.

[^2]: TCM, traditional Chinese medicine users.
